ライフサイエンスコーパス: N-omega-nitro-L-arginine

1 y-L-arginine, N omega-methyl-L-arginine, and N omega-nitro-L-arginine.

2 ga-nitro-L-arginine methyl ester (L-NAME) or N omega-nitro-L-arginine.

3 r stress and was blocked by the NO inhibitor N(omega)-nitro-L-arginine.

4 by the nitric oxide (NO) synthase inhibitors N(omega)-nitro-L-arginine (10 mg/kg) or N(omega)-nitro-L

5 that were unaffected by endothelium removal, N(omega)-nitro-L-arginine (10(- 4) mol/L, an NO synthase

6 N omega-nitro-L-arginine (100 micromol/L; nitric oxide a

7 n response to acetylcholine was inhibited by N(omega)-nitro-L-arginine (100 micromol/L) in all groups

8 N-omega-nitro-L-arginine (100 micromol/L) completely rev

9 osensitive interneurons that were blocked by N-omega-nitro-L-arginine (100 micromol/L).

10 iments, the nitric oxide synthase inhibitor, N omega-nitro-L-arginine (3 x 10(-4) M), was added to th

11 with N(omega)-nitro-L-arginine methyl ester, N(omega)-nitro-L-arginine (300 microM) was added.

12 was enhanced by arginine analogs, including N(omega)-nitro-l-arginine (a NO synthase inhibitor), sug

13 Pretreatment with N(omega)-nitro-L-arginine, a nitric oxide synthase inhib

14 N omega-nitro-L-arginine abolished nerve-induced relaxat

15 ino-sydonimine) nor a NO synthase inhibitor (N omega-nitro-L-arginine) altered FMLP- or IL-8-elicited

16 Furthermore, N(omega)-nitro-L-arginine, an inhibitor of NO synthesis,

17 The nitric oxide synthase inhibitor N omega-nitro-L-arginine blocked the induction of NMDA-L

18 hibition of nitric oxide synthase (NOS) with N(omega)-nitro-L-arginine during the 30-minute occlusion

19 urred after the administration of L-NAME and N omega-nitro-L-arginine in chronically instrumented ani

20 by N omega-nitro-L-arginine methyl ester or N omega-nitro-L-arginine, inhibitors of endogenous NO fo

21 nhibition of any of the NOS isoforms, unlike N omega-nitro-L-arginine itself, which does, although it

22 The nitric oxide (NO) synthase inhibitor N omega -nitro-L-arginine (L-NA, 100 microM; n = 16) abo

23 arginine and group 4 received L-arginine and N omega-nitro-L-arginine (L-NA), an inhibitor of NO synt

24 After N omega-nitro-L-arginine (L-NA; 100 microM) in the oral

25 N omega-nitro-L-arginine (L-NA; 100 microM) reduced the

26 N omega-nitro-L-arginine (L-NNA, NO synthase inhibitor)

27 ild-type mice treated with the NOS inhibitor N(omega)-nitro L-arginine (L-NA) and eNOS-deficient mice

28 ts were given the nonselective NOS inhibitor N(omega)-nitro-L-arginine (L-NA, 13 mg/kg i.v. [group II

29 temic nitric oxide synthase inhibition using N(omega)-nitro-L-arginine (L-NA, 30 mg/kg for 3 days), r

30 lockade of inhibitory neurotransmission with N(omega)-nitro-L-arginine (L-NA, a NO synthesis inhibito

31 The third and fourth groups were given N(omega)-nitro-L-arginine (L-NAME) (15 mg/kg/day) in dri

32 deoxycorticosterone acetate (DOCA)-salt and N(omega)-nitro-L-arginine (L-NNA) hypertensive but not n

33 nitric oxide synthase (NOS) inhibition using N(omega)-nitro-L-arginine (L-NNA) was also assessed, bec

34 Nonspecific blockade of NOS by N(omega)-nitro-L-arginine (L-NNA), but not by specific i

35 d before and after the NO synthase inhibitor N(omega)-nitro-L-arginine (L-NNA), L-NNA plus L-citrulli

36 N(omega)-nitro-L-arginine (L-NNA, 10(-4) mol/L) signific

37 e and during inhibition of NO synthesis with N(omega)-nitro-L-arginine (L-NNA, 35 mg/kg IV).

38 rotoporphyrin IX [SnPP IX] for CO synthesis, N(omega)-nitro-L-arginine [L-NNA] for NO synthesis, and

39 cible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expr

40 the local (direct) response was inhibited by N(omega)-nitro-L-arginine (LNA), and both local and cond

41 A(2) adenosine receptors, 10(-4) or 10(-3) M N(omega)-nitro-L-arginine (LNNA) to block nitric oxide p

42 Pretreatment with N omega-nitro-L-arginine methyl ester (100 micromol/L in

43 ion with the nitric oxide synthase inhibitor N omega-nitro-L-arginine methyl ester (11.2 +/- 3.7% inc

44 olus of the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (25 mg/kg), after

45 with a nitric oxide (NO) synthase inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME) or 7-nitr

46 demand after the systemic administration of N omega-nitro-L-arginine methyl ester (L-NAME) or N omeg

47 NOS inhibitors 7-nitroindazole (7-NI) and N omega-nitro-L-arginine methyl ester (L-NAME) produced

48 Furthermore, (100 mumol/L) N omega-nitro-L-arginine methyl ester (L-NAME), a nitric

49 ine and the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME), an incre

50 d NG-monomethyl-L-arginine (L-NMMA), but not N omega-nitro-L-arginine methyl ester (L-NAME), trans-st

51 nitric oxide (NO) was inhibited by 10(-4) M N omega-nitro-L-arginine methyl ester (L-NAME).

52 1-arginine, indomethacin, meclofenamate, or N omega-nitro-L-arginine methyl ester (L-NAME).

53 0(-5) mol/L; a cyclooxygenase inhibitor) and N omega-nitro-L-arginine methyl ester (L-NAME, 10(-4) mo

54 N omega-nitro-L-argininel-NA; 100 microM) or N omega-nitro-L-arginine methyl ester (L-NAME; 100 micro

55 and systemic inhibition of endogenous NO by N omega-nitro-L-arginine methyl ester (L-NAME; 100 mumol

56 At 190 mins, N omega-nitro-L-arginine methyl ester (L-NAME; 10mg/kg)

57 (Pe), sodium nitroprusside (Snp) with Pe, or N omega-nitro-L-arginine methyl ester (Lnam).

58 utaneous administration of 10 micrograms/min N omega-nitro-L-arginine methyl ester (NAME) for 48 hour

59 ot differ significantly between groups after N omega-nitro-L-arginine methyl ester administration.

60 and O2 consumption in vitro were blocked by N omega-nitro-L-arginine methyl ester or N omega-nitro-L

61 Pretreatment with N omega-nitro-L-arginine methyl ester to block NO synthe

62 y the competitive inhibitor of NO synthesis, N omega-nitro-L-arginine methyl ester, indicating that A

63 tion of the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester, reverses the vaso

64 After the administration of N omega-nitro-L-arginine methyl ester, systemic vascular

65 ith the nitric oxide (NO) synthase inhibitor N(omega) -nitro-l-arginine methyl ester (P > 0.05), indi

66 til inhibition of nitric oxide synthase with N(omega) -nitro-l-arginine methyl ester.

67 Mechanistically, blockade of eNOS with N(omega)-nitro-L-arginine methyl ester ( L-NAME) abolish

68 10(-5) mol/L), a transcription inhibitor; or N(omega)-nitro-L-arginine methyl ester (10(-4) mol/L), a

69 tors N(omega)-nitro-L-arginine (10 mg/kg) or N(omega)-nitro-L-arginine methyl ester (20 mg/kg) and th

70 N(omega)-nitro-L-arginine methyl ester (30 microM) parti

71 Pretreatment with N(omega)-nitro-l-arginine methyl ester (l-NAME) (10(-3)

72 o to 25 mM, but was unaffected by 100 microM N(omega)-nitro-L-arginine methyl ester (L-NAME) (68 +/-

73 was completely abolished in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME) (a nitri

74 ivity and, conversely, blockade of NOS using N(omega)-nitro-l-arginine methyl ester (l-NAME) inhibite

75 treated for 3.5 hours with 3 mM ATP or 2 mM N(omega)-nitro-L-arginine methyl ester (L-NAME) or 50 mi

76 rats was determined after administration of N(omega)-nitro-L-arginine methyl ester (L-NAME) or salin

77 N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhi

78 e substantially increased in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhi

79 arts generated 3 times more superoxide by an N(omega)-nitro-L-arginine methyl ester (L-NAME)-inhibita

80 ular response to long-term NOS inhibition by N(omega)-nitro-L-arginine methyl ester (L-NAME).

81 e increased significantly in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME).

82 Administration of N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/kg

83 ith either PBS or the NOS inhibitors ADMA or N(omega)-nitro-L-arginine methyl ester (L-NAME; each 250

84 ffects were totally reversed by provision of N(omega)-nitro-L-arginine methyl ester (NAME) in arginin

85 re measured before and during NO inhibition (N(omega)-nitro-l-arginine methyl ester [L-NAME]).

86 e have earlier shown that inhibitors of NOS (N(omega)-nitro-L-arginine methyl ester [L-NAME], 7-nitro

87 N(omega)-nitro-l-arginine methyl ester abolished the sys

88 N(omega)-Nitro-L-arginine methyl ester and 1H-[1,2,4]-ox

89 arterioles pretreated with ceramide, whereas N(omega)-nitro-l-arginine methyl ester had no effect.

90 epeated hypertensive challenges using either N(omega)-nitro-L-arginine methyl ester hydrochloride (L-

91 In the presence of DTT and the NO inhibitor N(omega)-nitro-L-arginine methyl ester hydrochloride, th

92 ing nitric oxide (NO) synthesis with L-NAME (N(omega)-nitro-L-arginine methyl ester hydrochloride; 5

93 t not by the nitric-oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester or by the vanillo

94 N(omega)-nitro-l-arginine methyl ester reduced vasodilat

95 signal regulated kinase (ERK) inhibitor, and N(omega)-nitro-L-arginine methyl ester, an antagonist of

96 ose-induced NOX4 expression was abrogated by N(omega)-nitro-l-arginine methyl ester, an inhibitor of

97 However, intracerebroventricular infusion of N(omega)-nitro-L-arginine methyl ester, an inhibitor of

98 -DAMP, charybdotoxin or BAPTA-AM, but not by N(omega)-nitro-L-arginine methyl ester, glipizide, indom

99 N(omega)-Nitro-L-arginine methyl ester, HOE-140, and dic

100 diator or NO released despite treatment with N(omega)-nitro-L-arginine methyl ester, N(omega)-nitro-L

101 nted eNOS glutathionylation and eNOS-derived N(omega)-nitro-L-arginine methyl ester-sensitive superox

102 Furthermore, N(omega)-nitro-L-arginine methyl ester-treated or eNOS-d

103 e was abolished by chronic administration of N(omega)-nitro-L-arginine methyl ester.

104 s well as when NO synthesis was inhibited by N(omega)-nitro-l-arginine methyl ester.

105 ent with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester.

106 retreated with a nonselective NOS inhibitor (N(omega)-nitro-L-arginine methyl ester; 30 mg/kg), a sol

107 L-NAME (N(omega)-nitro-L-arginine methyl ester; nitric oxide syn

108 Prior treatment of the ganglia with N-omega-nitro-L-arginine methyl ester (L-NAME), a nitric

109 to the left hindpaw to block CGRP responses; N-omega-nitro-l-arginine methyl ester (L-NAME), a nonsel

110 ith native LDL in the absence or presence of N-Omega-nitro-L-arginine methyl ester (L-NAME), a specif

111 travenously) with the NO synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME), or the c

112 Nitric oxide synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME, 3x10(-4)

113 xyl (TEMPOL,a superoxide dismutase-mimetic), N-omega-nitro-L-arginine methyl ester (L-NAME, a nitric

114 The inhibition of eNOS with N-omega-nitro-L-arginine methyl ester also potently redu

115 (NOS) inhibitors 7-nitroindazole (7-NI) and N-omega-nitro-L-arginine methyl ester also reduced NMDA

116 ence of the nitric oxide synthase inhibitors N-omega-nitro-L-arginine methyl ester and S-methyl-thioc

117 ment with a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine methyl ester, 50 mg/kg/day) or

118 N omega-Nitro-L-arginine-methyl-ester (L-NAME) augmented

119 Inhibition of NOS with N(omega)-nitro-L-arginine-methyl ester (L-NAME) signific

120 Moreover, l-NAME (N(omega)-nitro-l-arginine-methyl ester), a specific inhi

121 The actions of L-NA were mimicked by N omega-nitro-L-arginine methylester (L-NAME, 100 microM

122 ts of the nonselective NO synthase inhibitor N(omega)-nitro L-arginine methylester (L-NAME) in health

123 reated intraperitoneally with either L-NAME (N-omega-nitro-L-arginine methylester), a competitive inh

124 ence of the nitric oxide synthase inhibitor, N omega-nitro-L-arginine-methylester (10(-4) M).

125 Acetylcholine induced an N omega-nitro-L-arginine-methylester-sensitive vasodilat

126 reated rats-an effect that was attenuated by N omega-nitro-L-arginine-methylester.

127 bsence of nitric oxide synthetase inhibitor, N omega-nitro-L-arginine (NLA), was investigated in Mong

128 g to the equivalent complexes of nNOS, while N(omega)-nitro-L-arginine (NNA) binding produces a state

129 orn piglet brains and that pretreatment with N(omega)-nitro-L-arginine (NNLA), an inhibitor of nitric

130 The addition of N omega-nitro-L-arginine resulted in a reversal of the l